Lumen Biosciences Awarded $8.8M from U.S. DoD to Develop Fast-Acting, Intranasal Countermeasure Against Respiratory Viruses.
Lumen now has programs in development that target immune priming, kidney stone formation, cardiometabolic disease, and prevent or treat infections from viruses, bacteria, and parasites, all via oral or intranasal delivery.
And all are engineered biologics manufactured in cyanobacteria using electricity as the energy source.
The future is here.
